

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jun Wu		
U.S. Serial No.			
10/527,257	10/527,257		
U.S. Filing			
Date	March 9, 2005		
International			
Appln. No.:	PCT/CN2002/000631		
International			
Filing Date	09 September 2002 (09.09.2005)	Examiner:	Unknown
		Group Art	
Title:	TUMOR TAG AND THE USE THEREOF	Unit:	Unknown


**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail mailing label: EV 688439541 US

Date of Deposit: October 3, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Kim Anderson

Sir:

Pursuant to the requirements of § 1.821(e), I hereby state that in accordance with the requirements of § 1.824(d), a diskette containing a computer readable form of the Sequence Listing was filed in the above application, Serial No. 10/527,257, filed March 9, 2005, International Application No. PCT/CN2002/000631, International Filing Date September 9, 2002. The material on this diskette is identical in substance to the Sequence Listing appearing on pages 1-3 of the specification. No new matter has been added.

U.S. Serial No. 10/527,257, PCT Serial No. PCT/CN2002/000631
U.S. Filing Date: March 9, 2005, Int'l Filing Date September 9, 2002

Rec'd PCT/PTO 03 OCT 2005
Dkt. No. 186353/US


Applicant does not believe there are any fees with this Response. However, the Commissioner is hereby authorized to charge any deficiencies and/or credit any overpayments to Deposit Account No. 01-1420.

Respectfully submitted,

DORSEY & WHITNEY LLP

Customer Number 25763

Date: October 3, 2005

By: 
Min (Amy) S. Xu, (Reg. No. 39,536)
Phone: (612) 752-7367



UNITED STATES PATENT AND TRADEMARK OFFICE

Rec'd PCT/PTO

03 OCT 2005

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/527,257	Jun Wu	186353/US

25763
 DORSEY & WHITNEY LLP
 INTELLECTUAL PROPERTY DEPARTMENT
 50 SOUTH SIXTH STREET
 MINNEAPOLIS, MN 55402-1498

INTERNATIONAL APPLICATION NO.	
PCT/CN02/00631	
I.A. FILING DATE	PRIORITY DATE
09/09/2002	

DOCKETED

CONFIRMATION NO. 5292

371 FORMALITIES LETTER



OC000000016690560

RESPONSE DUE:

Oct 4, 2005 / Feb 4, 2006

Date Mailed: 08/04/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed

to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Rec'd PCT/PTO 03 OCT 2005

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/527,257	PCT/CN02/00631	186353/US

FORM PCT/DO/EO/922 (371 Formalities Notice)